The EQ-5D questionnaire is available from <https://euroqol.org/wp-content/uploads/2019/10/Sample_UK__English__EQ-5D-5L_Paper_Self_complete.pdf>. The VFQ-25 questionnaire is available from <https://www.rand.org/health-care/surveys_tools/vfq.html>. All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

Globally, it is estimated that the number of persons with both open angle glaucoma (OAG) and angle closure glaucoma (ACG) is rising dramatically. In 2010 Quigley et al estimated the worldwide prevalence of OAG and ACG combined was 60.5 million persons. This was projected to rise by 24% to 79.6 million persons by 2020. Similarly, the number bilaterally blind due to glaucoma was estimated to be 4.5 million for OAG and for 3.9 million for ACG in 2010 with a projected increase to 5.9 million for OAG and 5.3 million for ACG by 2020 \[[@pone.0232796.ref001]\]. In geographic terms Quigley et al showed that Sub-Saharan Africa (SSA) was the most adversely affected population globally with the highest ratio of glaucoma to adult population at 4.32% of the population in 2010. Such a disproportionate burden of glaucoma in SSA is further constrained by a lack of knowledge by the population as well as a lack of eye care resources and personnel. There is currently, for example, little understanding or consensus as to which glaucoma detection and treatment strategies are likely to be the most cost-effective in terms of the greatest number of sight years gained on a sustainable cost basis. Moreover, a recent literature review conducted by Smith et al (2018) determined that while a myriad of effective glaucoma control interventions exist in many urban centres throughout SSA, their widespread use and diffusion across SSA remains challenging principally due to their high cost and the lack of publicly funded eye health investments in glaucoma screening, detection and treatment alternatives \[[@pone.0232796.ref002]\]. This current situation across much of SSA exists despite the clear urgency of the problem at least as recognized by the global Vision 2020 coalition on blindness prevention and treatment \[[@pone.0232796.ref003]\]. In order to further inform the development of cost-effective strategies the aim of this project was to assess the patient and provider perceptions regarding glaucomas as well as their satisfaction with their specific therapy from both a cost and quality of life impact of primary open angle glaucoma.

Methods {#sec006}
=======

Current practice and opinions of professionals {#sec007}
----------------------------------------------

In addition to Ophthalmologists, Tanzania has a well-developed system of midlevel eye health workers who cater for the larger population that has no access to Ophthalmologists. The midlevel cadre consists of the Assistant Medical Officers (AMO-O), who specialize in clinical ophthalmology and cataract surgery; optometrists, ophthalmic nursing officers (ONO) and ophthalmic assistants. In the rural areas, eye clinics are mostly manned by AMO-Os, Ophthalmic nurses, Optometrists or any of the combinations. Patients are mostly seen by the midlevel cadre and, based on the competence or availability of facilities, are either managed at the same place or referred to a nearby regional hospital where an Ophthalmologist may be available. AMO-Os are trained to perform cataract surgery and emergency anterior segment surgeries like corneal lacerations. ONOs and optometrists are not trained to perform surgeries and therefore limit their services to medical treatment only. If resources at the regional hospital do not allow for appropriate treatment of the condition, a patient is referred to one of the 8 tertiary eye hospitals. There are several private eye hospitals with modern facilities in Tanzania, but they are beyond the reach of the majority.

In order to give an overall picture of the care provision on a countrywide/population basis a consensus meeting was convened in 2017. 22 health care professionals from throughout Tanzania attended in order to minimise bias. [Fig 1](#pone.0232796.g001){ref-type="fig"} shows the distribution and profession of participants.

![Distribution of consensus meeting participants (The map is taken from wikipedia file: Tanzania Districts.png. (2014, November 25).\
Wikimedia Commons, the free media repository. Retrieved 21.12, April 13, 2020 from https://commons.wiki,media.org/w/index.php?title = File:Tanzania_District.png&oldid = 140523089).](pone.0232796.g001){#pone.0232796.g001}

Opinions were sought on the proportions of glaucoma diagnoses attending, current management, patient adherence and attitudes, and concepts of 'ideal' practice in management of POAG. Finally, the content of a questionnaire to assess patient attitudes was agreed.

Costs and QOL impact patient views {#sec008}
----------------------------------

Ethical permission was granted by National Health Research Ethics Review Committee, National Institute for Medical Research, Tanzania ref NIMR/HQ/R.8a/Vol.IX/2683. Patients under active therapy attending Dr. Agarwal's Eye Hospital with Abu Baseer Specialist Eye clinic, Dar Es Salaam, Tanzania were invited to respond to three questionnaires delivered by two trained interviewers. All questionnaires were translated into Kiswahili and then back translated to ensure no loss of sense/meaning. All were delivered in Kiswahili. Convenience sampling of patients attending the glaucoma clinics were interviewed provided they gave free consent to participation and were capable understanding and responding to the questionnaires. Responses were on an anonymous basis with no personal identifiers or clinical information being collected.

The first questionnaire was the EQ5D-3L \[[@pone.0232796.ref004]\]. This is a validated method of measuring general patient utility and overall health status covering the domains of mobility, self-care, usual activities, discomfort and anxiety. Three response levels were used of no, moderate and extreme impact. In addition, the individuals indicated their perception of health on a Visual Analogue Scale where 0 was dead and 100 perfect health.

The second questionnaire was the VFQ25 \[[@pone.0232796.ref005]\]. This is a validated method of assessing self-perceived visual health status. Responses to each of the survey questions are converted to a numerical value between 0 and 100, and the responses aggregated to provide information on domains including, general health, visual health, ocular pain, near activities, distance activities, social functioning, mental health, role difficulties, dependency, driving, colour vision, peripheral vision and a composite score. A further six additional questions were selected for inclusion by the professionals in the consensus meeting. These were in the domains of near vision, distance vision \[[@pone.0232796.ref002]\], role limitations and well-being \[[@pone.0232796.ref002]\].

The third questionnaire was generated following discussion in the consensus meeting and related to glaucoma therapy and costs. This questionnaire was piloted and modified based on patient feedback before the final version was used. The key elements of this questionnaire related to age, gender, marital status, educational attainment, working status, average monthly income, principal occupation, payment for glaucoma drops, frequency of follow up visits, assistance with attending clinic visits, number of eye surgeries for glaucoma, frequency of eye drop usage, use of spectacles for near and distance vision, funding for treatment, travel times and travel costs associated with seeking treatment, waiting times for clinic visits, general impression with the glaucoma treatment received and overall willingness to pay for glaucoma surgery.

Sample size and analysis {#sec009}
------------------------

For the consensus meeting purposive sampling was used to ensure distribution of both levels and geographical location of care givers throughout Tanzania. For the patient questionnaires a target sample of a minimum of 118 patients was set in order to provide a margin of error of 9% with 95% confidence on questions with 50% response distribution \[[@pone.0232796.ref006]\]

Results of the consensus meeting and patient questionnaire were collated and presented using descriptive statistics. Analysis of the EQ5D and VF25 followed the methods adopted in prior literature in order to allow direct comparison \[[@pone.0232796.ref005],[@pone.0232796.ref014]\].

Results {#sec010}
=======

Current practice and opinions of professionals {#sec011}
----------------------------------------------

### Current management {#sec012}

POAG was identified as the single most common type of glaucoma presenting. All but one individual reported giving medical treatment as first line therapy to 95% or more patients. The remaining individual had a specialist practice and offered it to 85%. Reasons for medicine as first line therapy included the fact that for 12 of the attendees, medical treatment was the only available option. Many felt that offering surgery at an initial visit would intimidate patients returning to the centre and few centres offer this option. In addition, a fear of surgery was felt to exist in both patient and surgeons. Due to availability and affordability, timolol eye drops were the treatment of choice for a majority of participants.

Adherence to both prescribed therapy and repeat clinic appointments was a major issue. When asked the proportion of new patients that never returned the range was normally distributed from 2--60% with a mean of 18% and those only returning for 1 or two further visits a further 0--48% mean 19%. This varied hugely by practice and place, more rural settings having by far the highest proportion of non-adherents. Perceived reasons for not returning included poor awareness of the disease, costs involved for no appreciable gain and alternative health or social priorities. Since many of the patients are elderly, they depend on others for socio-economic support.

The hierarchy of importance placed on health seeking behaviour was discussed. It was felt that social and occupational demands took precedence over health. The group thought symptomatic eye conditions such as cataract received much better attention by patients especially since, unlike glaucoma, the therapy resulted in tangible visual improvement. The issue of traditional and spiritual healing was discussed. It was generally felt that the lack of symptoms contributed to a belief by individuals that they had been cured by such therapies meaning they no longer attended clinics for treatment.

### Ideal management {#sec013}

Optimal care pathways were discussed. Agreement was reached that a consultation time of 20 minutes for new and 15 minutes for follow-up was optimal with patients returning on average 3 or 4 times a year for review. Barriers to achieving this ideal were:

-   Lack of resource, human, equipment, therapy and training

-   Poor community/public awareness of the disease

-   Poor health care provider motivation towards the disease with concentration on cataract, lack of perceived impact and poor training.

-   Traditional and faith healing

Costs and QOL impact patient views {#sec014}
----------------------------------

### Demography {#sec015}

All 129 participants in this study completed the three questionnaires. The demographic distribution of participants is shown in [Table 1](#pone.0232796.t001){ref-type="table"} together with the demographic composition for mainland Tanzania from the 2012 census \[[@pone.0232796.ref007]\] and living wage \[[@pone.0232796.ref008]\] for comparison. Our sample differs from the national demography in several important aspects. In keeping with an age-related disease, the majority (71%) were aged 65+ years. Our population also had considerably more individuals with higher levels of education and occupation than the national census.

10.1371/journal.pone.0232796.t001

###### Responses of glaucoma patients attending the clinic in Dar-es-Salaam concerning demographic details.

![](pone.0232796.t001){#pone.0232796.t001g}

  Variable                                                                            Options                 Our sample N = 129   National demography Tanzania mainland 2012 census (7) N = 24,454,247
  ----------------------------------------------------------------------------------- ----------------------- -------------------- ----------------------------------------------------------------------
  Age                                                                                 15/24                   3 (2%)               93%
  25/34                                                                               2 (2%)                                       
  35/44                                                                               7 (5%)                                       
  45/54                                                                               14 (11%)                                     
  55/64                                                                               25 (19%)                                     
  65/74                                                                               46 (36%)                7%                   
  75+                                                                                 32 (25%)                                     
  Gender                                                                              Female                  50 (39%)             51%
  Highest education completed (denominator for percents 123 to match national data)   None                    6 (-)                
  Primary school                                                                      38 (31%)                83%                  
  Secondary school                                                                    49 (40%)                14%                  
  College                                                                             6 (5%)                  1%                   
  University/Post graduate                                                            30 (24%)                2%                   
  Occupation                                                                          Farmer/manual laborer   16 (12%)             76%
  Semi-skilled manual                                                                 16 (12%)                9%                   
  Skilled tradesperson                                                                26 (20%)                6%                   
  Professional                                                                        43 (33%)                3%                   
  Other                                                                               28 (21%)                5%                   
  Monthly income by taxation bracket (TZS)                                            0/169,999               44 (34%)             Living wage for individual (8)
  170,000/359,999                                                                     25 (19%)                211600--311000       
  360,000/539,999                                                                     19 (15%)                                     
  540,000/719,999                                                                     5 (4%)                                       
  720,000+                                                                            36 (28%)                                     

### EQ5D {#sec016}

[Table 2](#pone.0232796.t002){ref-type="table"} shows the main findings by domain. Over half (60%) reported no impact of their glaucoma on their health utility. The overall mean for the 5 EQ5D scores was 70 (range 18--94, SD 19).

10.1371/journal.pone.0232796.t002

###### Findings of EQ5D questionnaire by domain in 129 individuals receiving therapy for glaucoma in an ophthalmology outpatient department in Tanzania.

![](pone.0232796.t002){#pone.0232796.t002g}

  ----------------------------------------------------------------------
  EQ5D Domain          No Impact\   Moderate Impact\   Extreme Impact\
                       N (%)        N (%)              N (%)
  -------------------- ------------ ------------------ -----------------
  Mobility             71 (55)      51 (40)            7 (5)

  Self-care            111 (86)     16 (12)            2 (2)

  Usual activities     71 (55)      33 (26)            24 (19)

  Pain/discomfort      55 (43)      69 (54)            5 (4)

  Anxiety/depression   77 (55)      39 (30)            12 (10)

  Total--Average %     60%          32%                8%
  ----------------------------------------------------------------------

The visual analogue scale (VAS) showed 60% of respondents to place themselves between 40--70% health, generally following a normal distribution. Only 6 (5%) individuals gave scores below 30. The VAS score ranged from 10--100 with a mean value of 65 (SD 18).

### VFQ-25 {#sec017}

[Table 3](#pone.0232796.t003){ref-type="table"} shows the findings for the various domains of the VFQ-25 as well as responses to nine additional questions. In general, the higher the VFQ25 score, the better the persons reported health outcome was, with 0 denoting the lowest possible score a patient could give, to 100 being the highest overall value. This grading applies to Question 1 through 16, while for question 17 through 25, the situation was reversed with 0 denoting the least impact and 100 denoting the greatest impact \[[@pone.0232796.ref005]\] Overall, patients report a mean VFQ25 score of 42 (SD = 17) for their overall health, with a score of 65 (SD = 16) for general overall visual health. Similarly, patients reported relatively little ocular pain with the mean score of 78 (SD = 24). Both near and distance activities were quite adversely impacted with VFQ25 scores of 57 (SD = 31) and 56 (SD = 32), respectively. Role limitations also yielded a reduced VFQ25 score of 52 (SD = 32). Peripheral, colour and driving vision were moderately impacted with VFQ25 scores of 65 (SD = 32), 80 (SD = 31) and 68 (SD = 29), respectively. With respect to the additional questions, these proved moderately problematic for patient. Role limitation, reading and seeing the TV were more affected.

10.1371/journal.pone.0232796.t003

###### VFQ 25 Questionnaire findings in glaucoma patients attending the clinic in Dar-es-Salaam.

![](pone.0232796.t003){#pone.0232796.t003g}

                                                          N     Mean   Std. Deviation
  ------------------------------------------------------- ----- ------ ----------------
  Overall health (Q.1)                                    129   42     17
  Eyesight with correction both eyes Re Calculate (Q.2)   129   66     16
  Ocular pain (Q.4,19)                                    129   78     24
  Near activities (Q.5,6,7)                               119   57     31
  Distance Activities (Q.Q.8,9,14)                        91    56     32
  Social Functioning (Q.11,13)                            122   71     33
  Mental Health (Q.3,21,22,25)                            129   66     28
  Role Difficulties (Q.17,18)                             129   52     32
  Dependency (Q.20,23,24)                                 129   69     33
  Driving (Q.15c, 16,16a)                                 31    68     29
  Colour Vision (Q.12)                                    125   80     31
  Peripheral Vision (Q.10)                                129   65     32
  Near vision trouble reading (Q. A1)                     129   65     32
  Difficulty recognising across room (Q.A6)               128   83     24
  Difficulty seeing TV (Q.A8)                             129   70     32
  Role limitations (Q.A11 a and b)                        128   62     32
  Distress (Q.A12 and QA13)                               129   82     30

### Patient questionnaire {#sec018}

Individuals had travelled between 4 and 1500 Km to attend the appointment. About one third (36 (31%)) had travelled less than 10Km and another third (35 (31%)) had travelled between 10 and 100Km. 77 (60%) needed someone to come with them for their appointment. We extensively investigated associations with this need and found it weakly associated with increasing age (Chi^2^ = 8.4 p = 0.2 using all age categories and Chi^2^ = 4.1 p = 0.04 if age made binary by retirement age (\<55 and 55+ years)). It was also weakly associated (Chi^2^ 9.0 p = 0.06) with poor reported vision (VFQ-25 question 2). There was no association with income, education, distance travelled, overall feeling of wellbeing, occupation or their perception of the care they were receiving at the clinic. Other responses are shown in [Table 4](#pone.0232796.t004){ref-type="table"}.

10.1371/journal.pone.0232796.t004

###### Responses of glaucoma patients attending the clinic in Dar-es-Salaam relating to the costs associated with on-going therapy for glaucoma.

![](pone.0232796.t004){#pone.0232796.t004g}

  Question                                                                                               Options                    Finding
  ------------------------------------------------------------------------------------------------------ -------------------------- --------------------------------------------------------
  Do you need someone with you for a glaucoma checkup? N = 129                                           Yes                        77 (60%)
  Do you wear spectacles? N = 129                                                                        Distance                   59 (46%)
  Near                                                                                                   76 (59%)                   
  How long have you been on drops for glaucoma? N = 129                                                  No drops                   3 (2%)
  \<6 months                                                                                             20 (16%)                   
  6\>24 months                                                                                           32 (25%)                   
  24\>60 months                                                                                          31 (24%)                   
  \>60 months                                                                                            43 (33%)                   
  How often do you have a glaucoma check-up? N = 129                                                     Once a year                20 (16%)
  2--3 year^-1^                                                                                          54 (42%)                   
  4--5 year^-1^                                                                                          29 (22%)                   
  6+ year^-1^                                                                                            26 (20%)                   
  How much are you paying for drops each month? TZS N = 124                                              Mean (SD, range)           64782 (57813, 0--260000)
  Median (quartiles)                                                                                     50000 (22250--82500)       
  How much does it cost you to come to an appointment N = 126                                            Median (quartiles)         60000 (43000--100000)
  How long does it take you to travel to this appointment from the place where you are staying N = 128   Up to 2 hours              84 (of whom 9 living further away and staying locally)
  Over 2 hours                                                                                           44 (time up to 48 hours)   
  How do you pay for your appointments?                                                                  Self                       58 (46%)
  N = 126                                                                                                Self +                     20 (16%)
                                                                                                         Other                      48 (38%)
  How do you pay for your medical treatment?                                                             Self                       57 (47%)
  N = 122 (4 not on therapy)                                                                             Self +                     20 (16%)
                                                                                                         Other                      45 (37%)
  How do you pay for your surgery?                                                                       Self                       26 (46%)
  N = 57 (had surgery)                                                                                   Self +                     4 (7%)
                                                                                                         Other                      27 (47%)

Fifty-seven of participants (44%) had had at least one operation for glaucoma. This was not related to age, gender or monthly income. Time to travel to appointment was directly related to distance travelled showing internal consistency.

The median estimated total cost to attend for a glaucoma appointment was TZS 60000, at current exchange rates this is equivalent to £21.25. The median estimated cost of glaucoma drops per month was TZS 50,000. This was paid for by the patient themselves in 44% of cases (57/129) with a further 16% (20/129) covering some of the cost with assistance. The remainder were funded by alternative means including health insurance (45/129) or not on medication (7/129).

In order to make some comparison by individual between the cost of therapy per month and the reported monthly wage the monthly wage was taken as the mean of the range reported thus for each of the 25 individuals in the reported range TZS 170,000/359,999 the wage was placed as TZS 265000. The reported amount spent per month on drops was then expressed as a percentage of this amount. The results of this are shown in [Fig 2](#pone.0232796.g002){ref-type="fig"} with a further division illustrating in which way this was funded. It can be seen the most common method of self-pay took up to 25% of the monthly salary.

![Responses of glaucoma patients attending the clinic in Dar-es-Salaam concerning monthly medication cost expressed as a percentage of monthly salary.\
Each bar chart has the number of individuals colour coded by the method by which the medications are funded.](pone.0232796.g002){#pone.0232796.g002}

Discussion {#sec019}
==========

Our patient population differs from the national figures in several important aspects. It is not surprising that the age range is older since primary open angle glaucoma is strongly age related. The predominance of males in the patient population represents a gender bias in access to treatment as noted in other studies in Africa \[[@pone.0232796.ref009]\].

Our study was undertaken in a private eye hospital where all patients pay. In addition, this is in an urban setting. The hospital setting may explain the disproportionate number of individuals with higher income, occupational and educational status. None-the-less over one third of patients reported a monthly wage below the lower limit of the national living wage. Patients are required to pay consultation charges at every visit, however, should the patient express his/her inability to pay part or the whole amount at every visit then the counsellor takes the matter to the hospital manager who after considering the case can either waive off the consultation charges totally for the following visit or gives appropriate discount.

It has been shown that patients with lower educational status have poorer \[[@pone.0232796.ref010]\] and those with higher education status better health seeking behaviour \[[@pone.0232796.ref011]\]. Lower educational status individuals are also less likely to be aware of the disease process and treatment options \[[@pone.0232796.ref012]\].

The affordability of therapy has not been addressed in prior literature. Despite the bias towards professionals in our population, nearly 2/3rds of the patients earned less than TZS 540,000 a month (US dollars 235 at conversion rate of 1 USD = 2295) and one third a maximum of 170,000 TZS per month (USD 74) The mean cost of glaucoma drops per month as reported by the patients was TZS 64,782 (median 60,000). This is about 12% of the salary of the middle wage earners and more than a third of the salary of the minimum wage earners. This excludes other costs involved in the treatment. This important fact highlights the need for clinicians to explore this social aspect of the patient before prescribing and planning follow up visits of their patients to minimize the cost burden thereby increasing compliance. It is also important for the health policy makers to know this in the hope that they may consider offering some subsidy to the glaucoma patients on expensive medicines. This fact may tip the balance towards one time surgical intervention rather than life-long medication.

One interviewer gave an anecdotal impression of the feelings of a majority of the people they interviewed and the current situation. They felt the overwhelming burden for patients was economic. Patients have poor understanding around glaucoma, how it can be treated and why they have it. There is a disinterest in therapy when told there isn't a cure and preventing progression is the only course of action. The lack of trained clinicians and insufficient resource is a big issue when managing and treating the large number of patients. Education and resource improvement were seen to be a key factor in future development of glaucoma management.

EQ5D and VFQ25 {#sec020}
--------------

Questions relating to subjective opinions of wellbeing are inevitably prone to huge variability. Not only does an individual's perception of health vary (some regard themselves relative to prior severe illness whilst others have never experienced serious illness for example) but their perception may differ from day to day according to mood/events/social situation etc. The single question on the EQ5 using a visual analogue scale for general wellbeing showed an average of score of 65. The same question at the start of the VFQ25 was using words in 5 bins from excellent to poor and, when analysed by the accepted method, gave and average score of 42. We suggest this lack of internal consistency may be for two reasons. Firstly the EQ5D score ranges from best to worst imaginable health state whereas the scale in VF25 ranges from excellent to poor. We suggest that 'worst imaginable' is equivalent of 'very poor'. If the analysis is repeated using scores for the VF25 including a final category of very poor then the average score rises to 54. A second reason may be that people simply think in different ways when given a numeric scale and a verbal scale. This is strongly suggested by the fact that a majority considered their health good (71 (55%)) or fair (45 (35%)). Those who rated their health 'good' scored their health on the Likert scale 50 (14(20%)), 70 (14(20%)), 90 (13 (18%)). For the last of these scoring 90 there is little room for 'very good' and 'excellent'

The paucity of data from a comparable Sub-Saharan African population means direct comparison of our findings to EQ5D and VFQ25 measures for glaucoma patients is not possible. It is possible, however, to compare and contrast our findings to values obtained outside of SSA in other jurisdiction, albeit with the caveat that such comparison may not adequately reflect the provision of glaucoma services, nor the profile of glaucoma patients. To this end, various authors have reported a mean Visual Analogue Scale of ranging from 65 to 92 where 0 equals the worse possible outcome and 100 the best possible visual health status \[[@pone.0232796.ref013]\]. Similarly, Montemayor et al showed that the mean EQ5D scores among glaucoma patient in the Canadian Province of British Columbia was 81 (SD = 14) \[[@pone.0232796.ref014]\]. Aspinall et found that the mean value of the EQ-5D index among glaucoma patients in a clinic setting in Scotland was 76 (SD = 19) and that in patients with mild visual field loss, the mean EQ-5D index was 84 (SD = 17); in moderate visual field loss, 68 (SD = 21); and in severe visual field loss, 64 (SD = 26) \[[@pone.0232796.ref015]\]. More recently still, McDonald et al found that the mean EQ5D score in newly diagnosed POAG patients in England was 77 (SD = 22) \[[@pone.0232796.ref016]\]. Thus the EQ5D value obtained for our patients in Tanzania was at the lower range of EQ5D scores reported for the impact of glaucoma on patients. Our patients in Tanzania were much more likely to have moderate to severe perceived visual field loss associated which lower EQ5D scores, as found by Aspinall et al. \[[@pone.0232796.ref015]\] Whilst we did not collect clinical information, many papers have reported more severe disease in the clinic population in SSA compared to elsewhere \[[@pone.0232796.ref017]\].

In conclusion this study has the weaknesses discussed above of convenience sampling in an urban private clinic and use of subjective patient responses prone to lack of internal consistency. None-the-less the study has highlighted several key aspects relating to the current provision of care for glaucoma in SSA. A few are summarised below.

-   Non-adherence is a major issue, especially in rural settings where over 50% of the patients may fail to return for review.

-   Whilst medical therapy is overwhelmingly the first line treatment, the cost of maintaining this represents up to 25% of a patient's income which may tip the balance towards one-time costs such as surgical intervention

-   There is an impact of glaucoma on patients general well-being as determined by the EQ-5D and more tellingly on visual function with particular impact on role limitations as determined by the VF25

-   Despite our sample being taken in a private clinic and thus containing a much larger proportion of professionals than the general population, one third of the population earned \<TzS170,000 per month which is below the minimum wage.

These findings are of great importance for health care planners seeking to determine cost-effective, acceptable methods of both identifying and treating this major cause of preventable blindness. 3293
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a\) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b\) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <http://www.bmj.com/content/340/bmj.c181.long> for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see <http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories>.

We will update your Data Availability statement on your behalf to reflect the information you provide.

4\. We note that Figure 1 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: <http://journals.plos.org/plosone/s/licenses-and-copyright>.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

a)    You may seek permission from the original copyright holder of Figure 1 to publish the content specifically under the CC BY 4.0 license.  

We recommend that you contact the original copyright holder with the Content Permission Form (<http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf>) and the following text:

"I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (<http://creativecommons.org/licenses/by/4.0/>). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form."

Please upload the completed Content Permission Form or other proof of granted permissions as an \"Other\" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: "Reprinted from \[ref\] under a CC BY license, with permission from \[name of publisher\], original copyright \[original copyright year\]."

b)    If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder's requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): <http://viewer.nationalmap.gov/viewer/>

The Gateway to Astronaut Photography of Earth (public domain): <http://eol.jsc.nasa.gov/sseop/clickmap/>

Maps at the CIA (public domain): <https://www.cia.gov/library/publications/the-world-factbook/index.html> and <https://www.cia.gov/library/publications/cia-maps-publications/index.html>

NASA Earth Observatory (public domain): <http://earthobservatory.nasa.gov/>

Landsat: <http://landsat.visibleearth.nasa.gov/>

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): <http://eros.usgs.gov/#>

Natural Earth (public domain): <http://www.naturalearthdata.com/>

5\. Thank you for stating the following in the Financial Disclosure section:

\"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

    

We note that one or more of the authors are employed by a commercial company: Medmetrics Inc.

a)    Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

b\) Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I commend the authors for performing this interesting study which provides relevant and up to date information to the reader on the quality of life and cost of glaucoma care in a developing Sub Saharan African Country. however the following queries will need to be answered:

When was this study conducted ?

What was the inclusion criteria for enrolled participants, are there any exclusion criteria?

Table 1\...\... data for males should be included in the table

What in the authors opinion represent the salient limitations if any to their study?

The typographical errors in the manuscript should be corrected\....Line 39 and 362

Reviewer \#2: The authors investigate perceptions and local protocols of glaucoma treatment in Tansania during a local consensus meeting. Secondly they administered QoL questionnaires to a cohort of glaucoma patients.

Until now glaucoma blindness remains a mayor concern in rural Africa and so far there is no established gold standard for its treatment. The study questions are well outlined. The topic is relevant to practitioners in developing countries and beyond.

Focus group discussions revealed that most professionals still use drops as first line treatment; although limitations are known and obvious.

In their Discussions Authors should conclude that other treatment forms need to be implemented.

What about further surgical training for the midlevel cadre (AMO-O and ONOs)? Or shall we aim on building more specialized surgical glaucoma units?

I recommend to add some few extra lines on conclusions and recommendations.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Uche Nkechinyere J

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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14 Apr 2020

Dear Prof. Peters

Re The cost and quality of life impact of glaucoma in Tanzania: an observational study

Many thanks for your review of our paper. We are pleased to submit a revised version for consideration for publication. Our response to the comments is given below.

Journal requirements

All formatting detail has been revised as requested. Other specific points relating to Journal Requirements are:

3 a We have no ethical constraints exist for publication of anonymized data and have included the data-set in supplementary materials since we are advocates of data sharing where at all feasible. We would be grateful if you could update our Data Availability statement accordingly.

4 The map in Figure 1 is sourced from Wikipedia. Wikipedia explicitly states the material has been released into the public domain. The citation for this has been included in the figure caption.

The map is taken from Wikipedia file: Tanzania Districts.png. (2014, November 25). Wikimedia Commons, the free media repository. Retrieved 21.12, April 13, 2020 from <https://commons.wiki,media.org/w/index.php?title=File:Tanzania_District.png&oldid=140523089>

5 A revised financial disclosure reads as follows.

Amended Funding Statement:

Dr Andrew F. Smith is a consultant to Medmetrics Inc and was a paid health economics consultant on this project which was fully sponsored by The British Council for the Prevention of Blindness (BCPB). Dr Smith was involved in the overall study design, data analysis and manuscript preparation phases of the entire project.

The funder (BCPB) provided support in the form of salaries for authors \[AFS\] but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.

Competing Interests Statement:

Dr Andrew F. Smith is a consultant to Medmetrics Inc and was a paid health economics consultant on this project. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

No other authors have any competing interests to declare.

Review Comments to the Author

We are grateful to our reviewers for their time and expertise in assessing our manuscript. Our responses to their specific points are given below.

Reviewer \#1:

When was this study conducted ?

What was the inclusion criteria for enrolled participants, are there any exclusion criteria?

The consensus meeting was conducted in 2017. This has been added to the text.

The patient questionnaires were completed in 2018. Convenience sampling was used in glaucoma clinics. Exclusion criteria were non-consent to participation and inability to respond to the questionnaires. Both facts have been added to the text.

Table 1...\... data for males should be included in the table

Since gender is binary the proportion of males is a given once the proportion of females is stated. It is therefore not included for economy of space.

What in the authors opinion represent the salient limitations if any to their study?

We have discussed these in our discussion but agree a summary is beneficial for clarity hence have added the following to our conclusion:

'In conclusion this study has the weaknesses discussed above of convenience sampling in an urban private clinic and use of subjective patient responses prone to lack of internal consistency. None-the-less the.....'

10.1371/journal.pone.0232796.r003
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22 Apr 2020

The cost and quality of life impact of glaucoma in Tanzania: an observational study

PONE-D-19-34308R1

Dear Dr. Murdoch,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Remco PH Peters, MD, PhD, DLSHTM

Academic Editor

PLOS ONE
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14 May 2020
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The cost and quality of life impact of glaucoma in Tanzania: an observational study

Dear Dr. Murdoch:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof Remco PH Peters

Academic Editor

PLOS ONE
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